IP Library Granted Patent US 11,052,050
Granted Patent B2
US 11,052,050 · App. 15/351,973 · Granted Jul 6, 2021

Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same

Inventors: Philipp Harder (Heidelberg, DE); Olaf Fritz (Hirschhorn, DE); Ulf Fritz (Hirschhorn, DE)
Assignee: Varian Medical Systems, Inc.
A61K9/5031A61K9/1641A61K9/1694A61K9/5073A61K9/5078A61K9/5089A61K49/0404A61K49/0419
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,052,050
App. No.
15/351,973
Granted
Jul 6, 2021
Kind
B2
Abstract

Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy) phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Barium sulfate may also be provided to the core of the particles as a coating or absorbed within the core of the particles. The particles can be used to minimize blood flow to mammalian tissues by occluding at least a portion of a blood vessel of the mammal, or to deliver an active agent to a localized area within a body of a mammal by contacting a localized area with at least one of the particles. Farther, the particles are useful in sustained release formulations including active agent(s) for oral administration, as tracer particles for injection into the bloodstream of a mammal or for use in enhanced ultrasound imaging. The particles may include agents for increasing density for achieving useful buoyancy levels in suspension.

Claims (18)

1. A method of minimizing blood flow to a tissue in a mammal comprising occluding at least a portion of a blood vessel leading to the tissue with at least one particle, wherein the particle comprises a core and an outer coating, wherein the core comprises a hydrogel formed from an acrylic-based polymer and the outer coating comprises poly [bis (trifluoroethoxy) phosphazene] and/or a derivative thereof.

2. The method according to claim 1 , further comprising the step of delivering at least one active agent to the tissue with the particle as part of the occluding step.

3. The method according to claim 2 , wherein the at least one active agent is a cytostatic agent, an anti-inflammatory agent, an anti-mitogenic or cell proliferation active agent, an antineoplastic agent, a receptor-blocking agent, a steroid, or a hormone.

4. The method according to claim 1 , wherein the particle is porous and non-degradable.

5. The method according to claim 1 , wherein the core further comprises barium sulfate as a coating on the core and/or absorbed within the core.

6. A method of delivering an active agent to a localized area within a body of a mammal comprising contacting the localized area with at least one particle comprising a hydrogel acrylic-based polymer core, an outer coating comprising poly [bis (trifluoroethoxy) phosphazene] and/or a derivative thereof, and at least one active agent, such that an effective amount of the active agent is exposed to the localized area.

7. The method according to claim 6 , wherein the at least one active agent is a cytostatic agent, an anti-inflammatory agent, an anti-mitogenic or cell proliferation active agent, an antineoplastic agent, a receptor-blocking agent, a steroid, or a hormone.

8. The method according to claim 6 , wherein the active agent is delivered through the outer coating, and wherein the outer coating comprises the poly [bis (trifluoroethoxy) phosphazene] and/or a derivative thereof.

9. The method according to claim 8 , wherein the core further comprises barium sulfate as a coating on the core and/or absorbed within the core.

10. The method according to claim 6 , wherein the active agent is delivered in the core and diffuses through the outer coating.

11. The method according to claim 6 , wherein the particle is delivered in a formulation including a contrast agent selected from the group consisting of barium sulfate, tantalum compounds, gadolinium compounds and iodine-containing compounds.

12. A method of delivering an active agent to a localized area within the body of a mammal comprising contacting the localized area with at least one particle comprising an outer coating comprising poly [bis (trifluoroethoxy) phosphazene] and/or a derivative thereof, a core comprising an acrylic-based polymer hydrogel, and at least one active agent, such that an effective amount of the active agent is exposed to the localized area, wherein the particle comprises an agent to increase density.

13. The method according to claim 12 , wherein the agent to increase density is selected from the group consisting of deuterium oxide, cesium, at least one organic dye, barium sulfate, and combinations thereof.

14. The method according to claim 12 , wherein the at least one active agent is a cytostatic agent, an anti-inflammatory agent, an anti-mitogenic or cell proliferation active agent, an antineoplastic agent, a receptor-blocking agent, a steroid, or a hormone.

15. The method according to claim 12 , wherein the particle is pre-treated with cesium chloride to provide cesium to the particle.

16. The method according to claim 12 , wherein the core further comprises barium sulfate.

17. The method according to claim 16 , wherein the barium sulfate is present as a coating on the core.

18. The method according to claim 16 , wherein the barium sulfate is diffused within the core.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2020
From: BOSTON SCIENTIFIC CORPORATION
To: VARIAN MEDICAL SYSTEMS, INC.
Reel/Frame 051511/0504 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2019
From: HARDER, PHILIPP; FRITZ, OLAF; FRITZ, ULF
To: POLYZENIX GMBH
Reel/Frame 049821/0923 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2018
From: CELONOVA BIOSCIENCES GERMANY GMBH
To: BOSTON SCIENTIFIC LIMITED
Reel/Frame 045857/0368 →